Kane Biotech Inc. (CVE:KNE – Get Free Report) shares were down 20% on Tuesday . The company traded as low as C$0.02 and last traded at C$0.02. 132,200 shares traded hands during trading, a decline of 23% from the average daily volume of 171,277 shares. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The company’s 50-day simple moving average is C$0.03 and its 200-day simple moving average is C$0.03. The stock has a market capitalization of C$6.15 million, a price-to-earnings ratio of -1.50 and a beta of 1.08. The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Recommended Stories
- Five stocks we like better than Kane Biotech
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
